Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Non-Alcoholic Fatty Liver Disease (NAFLD) is caused by the accumulation of fat in over 5% of hepatocytes in the absence of alcohol consumption. NAFLD is considered the hepatic manifestation of metabolic syndrome (MS). Recently, an expert consensus suggested as more appropriate the term MAFLD (metabolic-associated fatty liver disease). Insulin resistance (IR) plays a key role in the development of NAFLD, as it causes an increase in hepatic lipogenesis and an inhibition of adipose tissue lipolysis. Beyond the imbalance of adipokine levels, the increase in the mass of visceral adipose tissue also determines an increase in free fatty acid (FFA) levels. In turn, an excess of FFA is able to determine IR through the inhibition of the post-receptor insulin signal. Adipocytes secrete chemokines, which are able to enroll macrophages inside the adipose tissue, responsible, in turn, for the increased levels of TNF-α. The latter, as well as resistin and other pro-inflammatory cytokines such as IL-6, enhances insulin resistance and correlates with endothelial dysfunction and an increased cardiovascular (CV) risk. In this review, the role of diet, intestinal microbiota, genetic and epigenetic factors, low-degree chronic systemic inflammation, mitochondrial dysfunction, and endoplasmic reticulum stress on NAFLD have been addressed. Finally, the clinical impact of NAFLD on cardiovascular and renal outcomes, and its direct link with type 2 diabetes have been discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Functional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387 · cited 1×
“Interestingly, the latter seems able to alter the metabolism of bile acids, affecting de novo lipogenesis and VLDL export processes [86].”
BackgroundSteatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 1×
“MiR-122 is the miRNA mostly expressed in the liver and its inhibition leads to decreased plasma cholesterol levels and an altered expression of liver genes involved in the synthesis of cholesterol and fatty acids [108].”
BackgroundEndoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes
Özcan, U., Cao, Q., Yilmaz, E., Lee, A.-H., Iwakoshi, N. N., Özdelen, E., Tuncman, G., Görgün, C., Glimcher, L. H., & Hotamisligil, G. S. (2004) · Science · doi:10.1126/science.1103160 · Cited by 3,844
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Topping, D. L., & Clifton, P. M. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1031 · Cited by 3,091
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760 · cited 3×
“insulin [49], the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and the Suppressor Of Cytokine Signaling-3 (SOCS-3) [50].”
BackgroundMacrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708 · cited 1×
“Moreover, the gut microbiota also represents the main source of endogenous alcohol production and its abnormalities associated with obesity are related to high alcohol levels [93].”
BackgroundIncreased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434 · cited 1×
“Patients with NAFLD show a significantly higher intestinal permeability and a larger bacterial proliferation of the small intestine as compared to healthy controls [83,84].”
BackgroundDresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 1×
“The protein resulting from the translation of this gene promotes the secretion of VLDL, while its variant rs58542926, through a loss of function, is associated with lower plasma VLDL levels, hepatic steatosis, and higher ALT levels [98].”
BackgroundLambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069 · cited 1×
“As already described, NAFLD patients display a de novo h patic lipogene is higher than healthy controls, which is neither suppressed in fasting nor with higher FFA plasma levels [41].”
BackgroundAdiponectin and AdipoR1 Regulate PGC-1α and Mitochondria by Ca2+ and AMPK/SIRT1
Iwabu, M., Yamauchi, T., Okada-Iwabu, M., Sato, K., Nakagawa, T., Funata, M., Yamaguchi, M., Namiki, S., Nakayama, R., Tabata, M., et al. (2010) · Nature · doi:10.1038/nature08991 · Cited by 971
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941 · cited 1×
“Hepatic exposure to increased levels of pro-inflammatory cytokines leads to histological changes typical of NASH, such as hepatocyte necrosis and apoptosis, neutrophil chemotaxis, activation of hepatic stellate cells, and production of Mallory bodies [114,115].”
BackgroundInsulin resistance: review of the underlying molecular mechanisms
Yaribeygi, H., Farrokhi, F. R., Butler, A. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27603 · Cited by 929 · cited 1×
“Genetically induced alterations triggering IR are heterogeneous and may affect the bond between insulin and its receptor, the autophosphorylation process, and the kinase activity of either IRS or PI3K or MAP kinase [19,20].”
BackgroundRyan, M. C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., O’Dea, K., Desmond, P. V., Johnson, N. A., & Wilson, A. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.012 · Cited by 778
Mitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753
Rivera, C. A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M., & Wallace, M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.019 · Cited by 693 · cited 1×
“Lipopolysaccharide (LPS) is among the most toxic products of bacterial derivation and can act as a toll-like receptor (TLR) ligand, with consequent activation of the inflammatory cascade and action on insulin signal, obesity, liver fat accumulation, and development and progression towards NASH (Figure 2) [90].”
BackgroundThe Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance
Watt, M. J., Miotto, P. M., De Nardo, W., & Montgomery, M. K. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00034 · Cited by 615 · cited 1×
“IR plays a key role in the development of NAFLD, as it causes an increase in hepatic lipogenesis and an inhibition of adipose tissue lipolysis, with a subsequent elevated flow of fatty acids in the liver [35,36].”
BackgroundEffects of weight loss on regional fat distribution and insulin sensitivity in obesity.
Goodpaster, B. H., Kelley, D. E., Wing, R. R., Meier, A., & Thaete, F. L. (1999) · Diabetes · doi:10.2337/diabetes.48.4.839 · Cited by 608
A Stress Signaling Pathway in Adipose Tissue Regulates Hepatic Insulin Resistance
Sabio, G., Das, M., Mora, A., Zhang, Z., Jun, J. Y., Ko, H. J., Barrett, T., Kim, J. K., & Davis, R. J. (2008) · Science · doi:10.1126/science.1160794 · Cited by 604
Spencer, M. D., Hamp, T. J., Reid, R. W., Fischer, L. M., Zeisel, S. H., & Fodor, A. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.049 · Cited by 593
Gregor, M. F., & Hotamisligil, G. S. (2007) · Journal of Lipid Research · doi:10.1194/jlr.r700007-jlr200 · Cited by 586 · cited 1×
“Adipocyte hypertrophy secondary to visceral obesity and IR causes an imbalance in the production of adipokines, which, in turn, affects the adipose tissue and the liver [57,58].”
BackgroundDongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533 · cited 1×
“Interestingly, this variant’s carriers, though presenting a higher risk of NAFLD progression, are burdened by an overall lower CV risk than controls, more likely due to reduced VLDL levels [99].”
BackgroundThe role of the microbiome in NAFLD and NASH
Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809302 · Cited by 523
Kim, Y.-B., Nikoulina, S. E., Ciaraldi, T. P., Henry, R. R., & Kahn, B. B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6928 · Cited by 487
Pessayre, D., & Fromenty, B. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.03.004 · Cited by 441
Gast, K. B., Tjeerdema, N., Stijnen, T., Smit, J. W. A., & Dekkers, O. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052036 · Cited by 403
Adaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374
Hotamisligil, G. S. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s73 · Cited by 352
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
Kleiner, D. E., & Makhlouf, H. R. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.011 · Cited by 303
Formation of methylamines from ingested choline and lecithin.
Zeisel, S. H., Wishnok, J. S., & Blusztajn, J. K. (1983) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33590-1 · Cited by 253
Kupffer cells mediate leptin-induced liver fibrosis
Wang, J., Leclercq, I., Brymora, J. M., Xu, N., Ramezani–Moghadam, M., London, R. M., Brigstock, D., & George, J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.011 · Cited by 210 · cited 1×
“In fact, Kupffer cells are stimulated by leptin to produce transforming growth factor-beta 1 (TGF-β1) and activate hepatic stellate cells [61] by “hedgehog” [62] and mTOR [63] pathways.”
BackgroundAbdelmalek, M. F., Lazo, M., Horska, A., Bonekamp, S., Lipkin, E. W., Balasubramanyam, A., Bantle, J. P., Johnson, R. J., Diehl, A. M., & Clark, J. M. (2012) · Hepatology · doi:10.1002/hep.25741 · Cited by 190
Sookoian, S., Castaño, G. O., & Pirola, C. J. (2014) · Gut · doi:10.1136/gutjnl-2013-305718 · Cited by 158 · cited 1×
“Although these data seem controversial, moderate alcohol consumption has also been suggested to exert a protective role against NAFLD [81].”
BackgroundZhou, Y.-Y., Zhou, X.-D., Wu, S.-J., Hu, X.-Q., Tang, B., Poucke, S. V., Pan, X.-Y., Wu, W.-J., Gu, X.-M., Fu, S.-W., et al. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001075 · Cited by 125
Mediterranean diet and NAFLD: what we know and questions that still need to be answered
Plaz Torres, M. C., Aghemo, A., Lleo, A., Bodini, G., Furnari, M., Marabotto, E., Miele, L., & Giannini, E. G. (2019) · Nutrients · doi:10.3390/nu11122971 · Cited by 97 · cited 1×
“Likewise, monounsaturated fats (typical of the Mediterranean diet) have shown beneficial effects in reducing the degree of IR and improving NAFLD [79,80].”
Background
Cited by
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Self-citationKorakas, E., Kountouri, A., Pavlidis, G., Oikonomou, E., Vrentzos, E., Michalopoulou, E., Tsigkou, V., Katogiannis, K., Pliouta, L., Balampanis, K., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae122 · Cited by 18
Diabetic Gastroparesis: Navigating Pathophysiology and Nutritional Interventions
Caturano, A., Cavallo, M., Nilo, D., Vaudo, G., Russo, V., Galiero, R., Rinaldi, L., Marfella, R., Monda, M., Luca, G., et al. (2024) · Gastrointestinal Disorders · doi:10.3390/gidisord6010016 · Cited by 17
Self-citationLiu, L., Zhou, Y., Liu, J., Zhang, X., He, C., Zeng, X., Dejenie, R., Zeb, U., Zeng, Q., Liu, L., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07005-0 · Cited by 13
“Closely linked to metabolic syndrome, NAFLD involves intricate pathological mechanisms, including dysregulated lipid metabolism, insulin resistance, oxidative stress, and inflammation [165–167].”
Shea, S., Lionis, C., Kite, C., Atkinson, L., Chaggar, S. S., Randeva, H. S., & Kyrou, I. (2021) · Biomedicines · doi:10.3390/biomedicines9111697 · Cited by 4
Metadata
- Authors
- Caturano, A., Acierno, C., Nevola, R., Pafundi, P. C., Galiero, R., Rinaldi, L., Salvatore, T., Adinolfi, L. E., & Sasso, F. C.
- Venue
- Processes
- Publisher
- MDPI AG
- Published
- 2021-01-11
- Volume
- 9
- Issue
- 1
- Pages
- 135
- ISSN
- 2227-9717 (ISSN-L)
- OpenAlex
- W3119110380
- Cited by
- 104
- References
- 45
- FWCI
- 11.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.